AMO Pharma Announces Update on Scientific Advice for Registrational Clinical Study of AMO-02 in Congenital Myotonic Dystrophy Type 1 Following Meetings with the U.S. Food and Drug Administration, the U.K. Medicines and Healthcare products Regulatory Agency and Health Canada

RegulatoryAMO-02Positive

AI Analysis

Summary

AMO Pharma announced regulatory guidance from the FDA, MHRA, and Health Canada on its registrational clinical study design for AMO-02 in Congenital Myotonic Dystrophy Type 1, with hospitalization as the planned primary outcome measure supported by functional assessment secondaries.

Clinical Trial Data

Phase

registrational

Outcome Details

Scientific advice received from FDA, MHRA, and Health Canada on registrational clinical study design

Importance:5/10

Sentiment:

0.40

regulatory guidanceclinical trial designrare diseaseFDAprimary endpointhospitalization

Related Companies

$HR $MEHA $HIT

Read the original article

Published by PR Newswire Pharma on July 6, 2026 9:49 PM

Read Original